{"entity":{"id":"paper-golan-brca-pancreatic-platinum-survival-bjc-2014","kind":"paper","name":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","aka":[],"tldr":"Among 71 people with pancreatic cancer and an inherited BRCA mutation, those with advanced disease lived 22 months on platinum chemotherapy against 9 months on other drugs, the clinical hint that led to the POLO trial.","summary":"Patients with BRCA1/2-associated pancreatic ductal adenocarcinoma diagnosed 1994 to 2012 were identified at three institutions: 71 patients (BRCA1 21, BRCA2 49, both 1), mean age 60.3, 81.7% with a family history of malignancy, 30% resected. Median overall survival for 58 analysable patients was 14 months; not reached for stage 1/2 (52% alive at 60 months) and 12 months for stage 3/4. Superior overall survival was observed for stage 3/4 patients treated with platinum against non-platinum chemotherapy (22 versus 9 months; P = 0.039).","asOf":"2026-09-24","links":[{"label":"Golan et al., Br J Cancer 2014: 71 BRCA carriers with pancreatic cancer, platinum and survival","url":"https://doi.org/10.1038/bjc.2014.418"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/25072261/"}],"tags":[],"related":["brca-germline"],"cancers":["pancreatic","brca-palb2-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":["brca"],"drugs":["folfirinox","gemcitabine-cisplatin"],"companies":[],"institutions":["sheba","princess-margaret"],"pathways":[],"terms":["gbrca-mutation"],"trials":[],"people":["talia-golan"],"bottlenecks":[],"keyPapers":[],"journals":["british-journal-of-cancer"],"dependsOn":[],"notes":[],"journal":"British Journal of Cancer","year":2014,"doi":"10.1038/bjc.2014.418","pmid":"25072261","authors":"Golan T, Kanji ZS, Epelbaum R, et al.","paperType":"observational","findings":["71 BRCA carriers: BRCA2 49, BRCA1 21.","Advanced disease: 22 months on platinum versus 9 on non-platinum."],"whatItMeans":"The retrospective platinum signal that made platinum-based first-line chemotherapy the standard for BRCA carriers and set POLO's design of olaparib after platinum.","caveats":["Retrospective, 58 analysable, three centres.","Treatment selection bias."],"changedPractice":false,"participants":71},"route":"/key-papers/paper-golan-brca-pancreatic-platinum-survival-bjc-2014/","neighbours":{"biomarker":[{"id":"brca-germline","kind":"biomarker","name":"Germline BRCA1/2 pathogenic variant (gBRCAm)","route":"/biomarkers/brca-germline/"}],"cancer":[{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"}],"drug":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/"}],"institution":[{"id":"princess-margaret","kind":"institution","name":"Princess Margaret Cancer Centre","route":"/institutions/princess-margaret/"},{"id":"sheba","kind":"institution","name":"Sheba Medical Center","route":"/institutions/sheba/"}],"term":[{"id":"gbrca-mutation","kind":"term","name":"Germline BRCA mutation (gBRCA)","route":"/terms/gbrca-mutation/"}],"person":[{"id":"talia-golan","kind":"person","name":"Talia Golan","route":"/people/talia-golan/"}],"journal":[{"id":"british-journal-of-cancer","kind":"journal","name":"British Journal of Cancer","route":"/journals/british-journal-of-cancer/"}],"trial":[{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/"}]}}